Actually these trials were about expanding Mitraclip's indications. The old EVEREST trial resulted in it being licensed for degenerative valve disease (damaged

Actually these trials were about expanding Mitraclip's indications. The old EVEREST trial resulted in it being licensed for degenerative valve disease (damaged valves), but here they wanted a license for treating otherwise healthy valves which are leaky due to being stretched open by a dilated ventricle in heart failure (functional valve disease).